CatalYm

CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and significantly improve treatment options for cancer patients. By making tumors re-accessible and vulnerable to a patient’s own immune system, CatalYm has devised an approach to overcome key limitations of existing immunotherapies and enhance survival rates and quality of life for cancer patients.